The EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial was the first study that evaluated CV outcomes with an SGLT2 inhibitor in patients at high risk for CV events.39 The study enrolled 7,020 participants with established CV disease who were followed for 3.1 years. Here, SLC5A2 is linked to type 2 diabetes mellitus.